Literature DB >> 33320755

Low-dose radiotherapy (LD-RT) for COVID-19-induced pneumopathy: a worth considering approach.

Fereshteh Koosha1, Atieh Pourbagheri-Sigaroodi2, Mohsen Bakhshandeh1, Davood Bashash2.   

Abstract

PURPOSE: It seems that 2020 would be always remembered by the name of novel coronavirus (designated as SARS-CoV-2), which exerted its deteriorating effects on the health care, economy, education, and political relationships. In August 2020 more than eight hundred thousand patients lost their lives due to acute respiratory syndrome. In the limited list of therapeutic approaches, the effectiveness of low-dose radiation therapy (LD-RT) for curing inflammatory-related diseases have sparkled a light that probably this approach would bring promising advantages for COVID-19 patients. LD-RT owns its reputation from its ability to modulate the host inflammatory responses by blocking the production of pro-inflammatory cytokines and hampering the activity of leukocytes. Moreover, the cost-effective and availability of this method allow it to be applied to a large number of patients, especially those who could not receive anti-IL-6 treatments in low-income countries. But enthusiasm for applying LD-RT for the treatment of COVID-19 patients has been muted yet.
CONCLUSION: In this review, we take a look at LD-RT mechanisms of action in the treatment of nonmalignant diseases, and then through studying both the dark and bright sides of this approach, we provide a thorough discussion if LD-RT might be a promising therapeutic approach in COVID-19 patients.

Entities:  

Keywords:  Anti-inflammation; COVID-19; Low-dose radiation therapy (LD-RT); Radiotherapy; Therapeutic approach

Year:  2021        PMID: 33320755     DOI: 10.1080/09553002.2021.1864049

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  3 in total

1.  Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial.

Authors:  Stefano Maria Magrini; Davide Tomasini; Emanuele Focà; Emirena Michela Garrafa; Navdeep Singh; Andrea Emanuele Guerini; Luca Triggiani; Roberto Bresciani; Diana Greco; Ludovica Pegurri; Salvatore LA Mattina; Elena Ranghetti; Giulia Volpi; Roberto Maroldi; Michela Buglione; Luigi Spiazzi
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

Review 2.  Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations.

Authors:  Edward J Calabrese; Walter J Kozumbo; Rachna Kapoor; Gaurav Dhawan; Pedro C Lara; James Giordano
Journal:  Radiother Oncol       Date:  2021-04-28       Impact factor: 6.901

Review 3.  Covid-19 and radiotherapy: a systematic review after 2 years of pandemic.

Authors:  Antonio Piras; Valeria Venuti; Andrea D'Aviero; Davide Cusumano; Stefano Pergolizzi; Antonino Daidone; Luca Boldrini
Journal:  Clin Transl Imaging       Date:  2022-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.